We expect overall revenue growth to remain low, due to the continued impact of the decline in legacy drug sales. As always, the three main oncology drugs will continue to support the topline, although there could be an uptick in Tamiflu’s sales. Some of the recently launched drugs such as Perjeta and Kadcyla are likely to contribute greatly to incremental revenues.